TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic ...
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers - demonstrated responses in 15 different cancer types across four separate studies Data presented at ESMO GI 2019 from TYME-88-PANC Phase II study …